- Clinical Interests
- Pituitary disease
- Endocrine manifestations of AIDS
- Medical Education
- MD, University of Rochester School of Medicine and Dentistry
- Residency, New York Presbyterian Hospital
- Fellowship, Massachusetts General Hospital
- Board Certifications
- Diabetes & Metabolism
- Boston: Massachusetts General Hospital
- Insurances Accepted
- Aetna Health Inc.
- Beech Street
- Blue Cross Blue Shield - Blue Care 65
- Blue Cross Blue Shield - Indemnity
- Blue Cross Blue Shield - Managed Care
- Blue Cross Blue Shield - Partners Plus
- Cigna (PAL #'s)
- Fallon Community HealthCare
- Great-West Healthcare (formally One Health Plan)
- Harvard Pilgrim Health Plan - ACD
- Harvard Pilgrim Health Plan - PBO
- Harvard Pilgrim Health Plan - SSN
- Health Care Value Management (HCVM)
- Humana/Choice Care PPO
- Medicare - ACD
- Neighborhood Health Plan - ACD
- Neighborhood Health Plan - PBO
- OSW - Maine
- OSW - New Hampshire
- OSW - Rhode Island
- Private Health Care Systems (PHCS)
- Senior Whole Health
- Tufts Health Plan
- United Healthcare (non-HMO) - ACD
- United Healthcare (non-HMO) - PBO
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
- Patient Age Group
- Research Summary
- Dr. Grinspoon is a clinical researcher who studies the development of novel neuroendocrine strategies to reduce cardiovascular and metabolic risk associated with excess visceral fat, with a focus on the use of growth hormone releasing hormone (GHRH) to increase endogenous pulsatile GH, and selectively reduce visceral fat. His research interests include metabolic consequences of visceral fat accumulation in lipodystrophy and obesity.
- Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Effects of Rosiglitazone on Metabolic Indices and Fat in HIV Lipodystrophy: A Randomized Controlled Trial. Ann Intern Med. 2004; 140: 786 - 794.
Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger B, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S. Metabolic Effects of a Growth Hormone-Releasing Factor in HIV Patients. N Engl J Med 2007; 357:2359-70.
Lo J, You SM, Canavan B, Liebau J, Beltrani G, Koutkia P, Hemphill L, Lee H, Grinspoon S. Low Dose Physiologic Growth Hormone in HIV Patients with Abdominal Fat Accumulation: A Randomized Controlled Trial. JAMA. 2008; 300:509-519. PMCID: PMC2532757
Subramanian S*, Tawakol A*, Burdo T, Abbara S, Wei, J, Vijayakumar J, Corsini E, Abdelbarky A, Zanni M, Hoffman U, Williams K, Lo J?, Grinspoon S?. Arterial Inflammation in HIV-Infected Patients. JAMA 2012. Jul 25;308(4):379-86. PMCID: PMC3724172
Stanley TL, Feldpausch M, Oh J, Branch K, Lee H, Torriani M, Grinspoon SK. Effects of Tesamorelin on Visceral Fat and Liver Fat in HIV-infected Patients with Abdominal Fat Accumulation: A Randomized Clinical Trial. JAMA. 2014 Jul 23-30;312(4):380-9. PMID:25038357
A Massachusetts General Hospital-based study finds that initiating antiretroviral therapy soon after diagnosis of an HIV infection did not prevent the progression of significant arterial inflammation in a small group of previously untreated patients.
REPRIEVE, Largest HIV-related Cardiovascular Disease Clinical Trial Ever, Enrolls More Than 1,000 Participants
One year ago, the National Institutes of Health launched REPRIEVE – The Randomized Trial to Prevent Vascular Events in HIV study, designed to investigate whether statin use can prevent cardiovascular disease in people living with HIV. To date, the trial has enrolled nearly 1,200 participants across approximately 85 trial sites.
The first clinical trial to investigate whether treatment with a statin drug can reduce the increased cardiovascular disease risk in people infected with HIV has begun enrolling patients. Based at the MGH, the six-year, $40 million REPRIEVE (Randomized Study to Prevent Vascular Events in HIV) trial will be conducted at around 100 sites in the U.S., Canada, Puerto Rico and Thailand.
A nationwide study based at MGH will investigate, for the first time, whether treatment with a statin drug can reduce the elevated risk of cardiovascular disease in individuals infected with the human immunodeficiency virus.
The only drug to receive FDA approval for reduction of the abdominal fat deposits that develop in some patients receiving antiviral therapy for HIV infection may also reduce the incidence of fatty liver disease in such patients.
Differences in plaque composition, immune activation may explain elevated cardiovascular risk in HIV-infected women
An MGH research team has discovered a possible mechanism behind the elevated risk of cardiovascular disease in women infected with HIV, a risk even higher than that of HIV-infected men.
The elevated risk of cardiovascular disease seen in patients infected with HIV appears to be associated with increased inflammation within the arteries, according to a study in a special issue of JAMA published in conjunction with the International AIDS Conference.
Treatment with the common diabetes drug metformin appears to prevent progression of coronary atherosclerosis in patients infected with HIV.
video featuring MGH investigator Steven Grinspoon
55 Fruit Street
Boston, MA 02114-2696
55 Fruit Street
Boston, MA 02114-2696
Phone 1: 617-726-7948
Phone 2: 617-726-6813